MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval and the market launch of CareLink® Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. The software analyzes data from a patient’s insulin pump, continuous glucose monitoring (CGM) device, and blood glucose meter to identify the most important patient information in one easy-to-use dashboard. In addition, the software offers therapy considerations that clinicians can use as a starting point to discuss therapy changes with their patients to help improve glucose control.